Systemic effects of hyperthermic isolated lower limb perfusion with carboplatin and interferon-beta.
The changes in systemic circulation during hyperthermic isolated lower limb perfusion with carboplatin and interferon-beta were investigated in 19 patients with malignant melanoma. The cardiac output (CO) increased significantly (p < 0.01) from 3.81 +/- 0.22 L/min before the procedure to 5.30 +/- 0.49 L/min 1 h after hyperthermic perfusion. The double product (mean arterial pressure x heart rate) also increased significantly (p < 0.01) from 5,145 +/- 372 mm Hg/min to 6,760 +/- 486 mm Hg/min. In some patients, it increased to more than twice the control value. These changes were accompanied by an increase in body temperature, presumably caused by the systemic leakage of both warmed blood and interferon-beta. Blood chemistry data demonstrated no significant changes in the liver or renal function. However, the serum CPK level increased markedly on the first postoperative day, and persisted for 1 week, thus suggesting that some muscle damage occurred during the procedure. There was no operative death or severe complications. From these data, we concluded that hyperthermic isolated limb perfusion with interferon-beta is a relatively safe therapeutic method for malignant melanoma of the extremities. However, care should be taken in patients with ischemic heart disease who may suffer a heart attack due to the rapid increase in cardiac work during the procedure.
Tominaga
R
R
Department of Cardiovascular Surgery , Kyushu University Faculty of Medicine, Fukuoka, Japan.
Nakano
T
T
Shibata
S
S
Siraishi
K
K
Nagae
S
S
Nakayama
J
J
Yasui
H
H
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001831:Body Temperature; D016190:Carboplatin / Q000008:administration & dosage; D002302:Cardiac Output; D010478:Chemotherapy, Cancer, Regional Perfusion; D003402:Creatine Kinase / Q000097:blood; D005260:Female; D006439:Hemodynamics; D006801:Humans; D006979:Hyperthermia, Induced; D016899:Interferon-beta / Q000008:administration & dosage; D007866:Leg; D008297:Male; D008545:Melanoma / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology
D016899:Interferon-beta; D016190:Carboplatin; D003402:Creatine Kinase